Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Challenges faced when identifying patients for combination immunotherapy.
Ernstoff MS, Gandhi S, Pandey M, Puzanov I, Grivas P, Montero A, Velcheti V, Turk MJ, Diaz-Montero CM, Lewis LD, Morrison C. Ernstoff MS, et al. Among authors: grivas p. Future Oncol. 2017 Aug;13(18):1607-1618. doi: 10.2217/fon-2017-0218. Epub 2017 Aug 24. Future Oncol. 2017. PMID: 28835114 Review.
Immunotherapy of kidney cancer.
Grivas PD, Redman BG. Grivas PD, et al. Curr Clin Pharmacol. 2011 Aug;6(3):151-63. doi: 10.2174/157488411797189406. Curr Clin Pharmacol. 2011. PMID: 21827390 Review.
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.
Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, Garcia JA, Grivas P. Ornstein MC, et al. Among authors: grivas p. Urol Oncol. 2018 Sep;36(9):405-412. doi: 10.1016/j.urolonc.2018.02.018. Epub 2018 Mar 30. Urol Oncol. 2018. PMID: 29606341 Review.
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG Jr, Finke JH, Barata PC, Lamenza M, Devonshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, Garcia JA, Gilligan TD, Ornstein MC, Grivas P. Tzeng A, et al. Among authors: grivas p. Target Oncol. 2018 Oct;13(5):599-609. doi: 10.1007/s11523-018-0595-9. Target Oncol. 2018. PMID: 30267200
Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma.
Sheng IY, Diaz-Montero CM, Rayman P, Wei W, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Company D, Stephenson A, Campbell S, Haber G, Lee B, Mian O, Gilligan TD, Rini BI, Garcia JA, Grivas P, Ornstein MC. Sheng IY, et al. Among authors: grivas p. Target Oncol. 2020 Apr;15(2):211-220. doi: 10.1007/s11523-020-00707-z. Target Oncol. 2020. PMID: 32207064
Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival.
Fallah J, Diaz-Montero CM, Rayman P, Wei W, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Dann P, Company D, Stephenson A, Campbell S, Haber G, Lee B, Mian O, Gilligan T, Garcia JA, Rini B, Ornstein MC, Grivas P. Fallah J, et al. Among authors: grivas p. Clin Genitourin Cancer. 2020 Dec;18(6):500-508. doi: 10.1016/j.clgc.2020.03.004. Epub 2020 Mar 19. Clin Genitourin Cancer. 2020. PMID: 32340875
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.
Pal SK, Somford DM, Grivas P, Sridhar SS, Gupta S, Bellmunt J, Sonpavde G, Fleming MT, Lerner SP, Loriot Y, Hoffman-Censits J, Valderrama BP, Andresen C, Schnabel MJ, Cole S, Daneshmand S. Pal SK, et al. Among authors: grivas p. Future Oncol. 2022 Jul;18(21):2599-2614. doi: 10.2217/fon-2021-1629. Epub 2022 May 24. Future Oncol. 2022. PMID: 35608106 Free article.
290 results